Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JR8603 in advanced solid tumors
NCT06783569Phase 1Recruiting
- Sponsor
- JiaRay Group
- Start
- Dec 2024
- Primary completion
- May 2026
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of JR8603 in solid tumor, gastric cancer (GC), esophagogastric junction cancer and 1 more (9 arms), sponsored by JiaRay Group. Primary endpoints: Adverse Events (Including Serious Adverse Events) up to 1 year, Dose-Limiting Toxicity up to 1 year and 2 more. Started Dec 2024; status: recruiting.
02
Drugs
JR8603
03
Conditions
solid tumorgastric cancer (GC)esophagogastric junction cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06783569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06783569.